L-selenomethionine reduces platinum(IV) anticancer model compounds at strikingly faster rates than L-methionine
L-Selenomethionine (SeMet), the predominant form of selenium acquired from the diet by humans, has been used as a supplement, and exhibit some important functions like cancer prevention and antioxidative defense. Its interactions with Pt(II) anticancer drugs have been characterized, but its redox re...
Saved in:
Published in: | Dalton transactions : an international journal of inorganic chemistry Vol. 43; no. 41; p. 15328 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
07-11-2014
|
Subjects: | |
Online Access: | Get more information |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | L-Selenomethionine (SeMet), the predominant form of selenium acquired from the diet by humans, has been used as a supplement, and exhibit some important functions like cancer prevention and antioxidative defense. Its interactions with Pt(II) anticancer drugs have been characterized, but its redox reactions with platinum(IV) anticancer prodrugs have not been exploited. In this work, the oxidation of SeMet by Pt(IV) anticancer model compounds trans-[PtX2(CN)4](2-) (X = Cl, Br) was characterized. A stopped-flow spectrometer was used to record the rapid scan spectra and to follow the reaction kinetics over a wide pH range. An overall second-order rate law was derived: -d[Pt(IV)]/dt = k'[Pt(IV)][SeMet], where k' pertains to the observed second-order rate constants. The k'-pH profiles showed that k' increased only about 6 times even though the solution pH was varied from 0.25 to 10.5. The redox stoichiometry was determined as Δ[Pt(IV)]/Δ[SeMet] = 1 : (1.07 ± 0.07), suggesting that SeMet was oxidized to selenomethionine selenoxide. The selenoxide together with its hydrated form was identified explicitly by high resolution mass spectral analysis. A reaction mechanism was proposed which encompassed three parallel rate-determining steps relying on the protolytic species of SeMet. Rate constants of the rate-determining steps were obtained from the simulations of the k'-pH profiles. Activation parameters were determined for the reactions of the zwitterionic form of SeMet with the Pt(IV) complexes. A bridged electron transfer process is delineated in the rate-determining steps and several lines of evidence support the bridged electron transfer mode. Strikingly, reduction of [PtX2(CN)4](2-) by SeMet is 3.7 × 10(3)-5.7 × 10(4) times faster than that by L-methionine. Some potential biological consequences resulting from the strikingly fast reduction are discussed. |
---|---|
AbstractList | L-Selenomethionine (SeMet), the predominant form of selenium acquired from the diet by humans, has been used as a supplement, and exhibit some important functions like cancer prevention and antioxidative defense. Its interactions with Pt(II) anticancer drugs have been characterized, but its redox reactions with platinum(IV) anticancer prodrugs have not been exploited. In this work, the oxidation of SeMet by Pt(IV) anticancer model compounds trans-[PtX2(CN)4](2-) (X = Cl, Br) was characterized. A stopped-flow spectrometer was used to record the rapid scan spectra and to follow the reaction kinetics over a wide pH range. An overall second-order rate law was derived: -d[Pt(IV)]/dt = k'[Pt(IV)][SeMet], where k' pertains to the observed second-order rate constants. The k'-pH profiles showed that k' increased only about 6 times even though the solution pH was varied from 0.25 to 10.5. The redox stoichiometry was determined as Δ[Pt(IV)]/Δ[SeMet] = 1 : (1.07 ± 0.07), suggesting that SeMet was oxidized to selenomethionine selenoxide. The selenoxide together with its hydrated form was identified explicitly by high resolution mass spectral analysis. A reaction mechanism was proposed which encompassed three parallel rate-determining steps relying on the protolytic species of SeMet. Rate constants of the rate-determining steps were obtained from the simulations of the k'-pH profiles. Activation parameters were determined for the reactions of the zwitterionic form of SeMet with the Pt(IV) complexes. A bridged electron transfer process is delineated in the rate-determining steps and several lines of evidence support the bridged electron transfer mode. Strikingly, reduction of [PtX2(CN)4](2-) by SeMet is 3.7 × 10(3)-5.7 × 10(4) times faster than that by L-methionine. Some potential biological consequences resulting from the strikingly fast reduction are discussed. |
Author | Huo, Shuying Shi, Tiesheng Dong, Jingran Shen, Shigang Xu, Jianzhong Ren, Yanli Song, Changying |
Author_xml | – sequence: 1 givenname: Shuying surname: Huo fullname: Huo, Shuying email: shensg@hbu.edu.cn, rock@hbu.edu.cn organization: College of Chemistry and Environmental Science, and the MOE Key Laboratory of Medicinal Chemistry and Molecular Diagnostics, Hebei University, Baoding 071002, Hebei Province, P. R. China. shensg@hbu.edu.cn rock@hbu.edu.cn – sequence: 2 givenname: Jingran surname: Dong fullname: Dong, Jingran – sequence: 3 givenname: Shigang surname: Shen fullname: Shen, Shigang – sequence: 4 givenname: Yanli surname: Ren fullname: Ren, Yanli – sequence: 5 givenname: Changying surname: Song fullname: Song, Changying – sequence: 6 givenname: Jianzhong surname: Xu fullname: Xu, Jianzhong – sequence: 7 givenname: Tiesheng surname: Shi fullname: Shi, Tiesheng |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25075569$$D View this record in MEDLINE/PubMed |
BookMark | eNpFj81KxDAYRYMozji68QEkS11Uk_QnyVIGfwYKbtTt8CX5xom2SWnSxby9BRVXFw6XA-eMHIcYkJBLzm45K_WdrVxmvBbKHJElr6QstCirBTlL6ZMxIVgtTslC1EzWdaOXJLZFwg5D7DHvfQw-IB3RTRYTHTrIPkz99eb9hkLI3kKwONI-Ouyojf0Qp-AShUxTHv2XDx_dge4g5fk0Qp4VeQ-BtsW__Jyc7KBLePG7K_L2-PC6fi7al6fN-r4trFAyF2BcqXSllZJ10wjFDQdV6bJRIJ0wHI3kUM7QqEbqHZi5R0ElmJIatZViRa5-vMNkenTbYfQ9jIftX7n4BpGEW88 |
CitedBy_id | crossref_primary_10_1039_C5NJ01103E crossref_primary_10_1016_j_bmcl_2016_07_046 crossref_primary_10_1007_s11243_019_00347_x crossref_primary_10_1039_C8CC05682J crossref_primary_10_1007_s11243_015_9923_4 crossref_primary_10_1007_s11243_017_0125_0 crossref_primary_10_1016_j_molliq_2020_115195 crossref_primary_10_1007_s11243_016_0021_z crossref_primary_10_1039_c5mt00116a crossref_primary_10_1007_s11243_019_00311_9 crossref_primary_10_1039_C7DT00885F crossref_primary_10_2174_2212796816666220422134828 crossref_primary_10_1007_s11243_015_9995_1 crossref_primary_10_1021_acs_joc_3c00104 crossref_primary_10_1039_C6DT01804A crossref_primary_10_1016_j_molliq_2018_09_056 crossref_primary_10_1002_kin_21107 crossref_primary_10_1021_acs_joc_1c02793 crossref_primary_10_1016_j_saa_2019_117328 crossref_primary_10_1093_mtomcs_mfad020 crossref_primary_10_1007_s11243_015_9983_5 crossref_primary_10_1016_j_molliq_2019_112105 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1039/c4dt01528b |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 1477-9234 |
ExternalDocumentID | 25075569 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -DZ -JG -~X 0-7 0R~ 29F 2WC 4.4 53G 5GY 70~ 7~J AAEMU AAIWI AAJAE AAMEH AANOJ AAWGC AAXHV AAXPP ABASK ABDVN ABEMK ABJNI ABPDG ABRYZ ABXOH ACGFS ACIWK ACLDK ACNCT ADMRA ADSRN AEFDR AENEX AENGV AESAV AETIL AFLYV AFOGI AFRDS AFVBQ AGEGJ AGKEF AGRSR AHGCF ALMA_UNASSIGNED_HOLDINGS ANBJS ANUXI APEMP ASKNT AUDPV AZFZN BLAPV BSQNT C6K CGR CS3 CUY CVF D0L DU5 EBS ECGLT ECM EE0 EF- EIF EJD F5P GGIMP GNO H13 HZ~ H~N IDZ J3G J3H J3I M4U NPM O9- R7B R7C RAOCF RCNCU RNS ROL RPMJG RRA RRC RSCEA SKA SKF SLH TN5 TWZ UCJ UPT VH6 VQA WH7 XOL |
ID | FETCH-LOGICAL-c287t-abd38949887566281b1a849368a7d2b1eb71a3b1ab8679fab0758a420879e9c72 |
IngestDate | Sat Sep 28 08:04:48 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 41 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c287t-abd38949887566281b1a849368a7d2b1eb71a3b1ab8679fab0758a420879e9c72 |
PMID | 25075569 |
ParticipantIDs | pubmed_primary_25075569 |
PublicationCentury | 2000 |
PublicationDate | 2014-11-07 |
PublicationDateYYYYMMDD | 2014-11-07 |
PublicationDate_xml | – month: 11 year: 2014 text: 2014-11-07 day: 07 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Dalton transactions : an international journal of inorganic chemistry |
PublicationTitleAlternate | Dalton Trans |
PublicationYear | 2014 |
SSID | ssj0022052 |
Score | 2.2907429 |
Snippet | L-Selenomethionine (SeMet), the predominant form of selenium acquired from the diet by humans, has been used as a supplement, and exhibit some important... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 15328 |
SubjectTerms | Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Drug Interactions Methionine - chemistry Methionine - pharmacology Models, Molecular Organoplatinum Compounds - chemistry Organoplatinum Compounds - pharmacology Oxidation-Reduction Selenomethionine - chemistry Selenomethionine - pharmacology Spectrophotometry |
Title | L-selenomethionine reduces platinum(IV) anticancer model compounds at strikingly faster rates than L-methionine |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25075569 |
Volume | 43 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LTxsxELaScmgvqKUvKFQ-9FC0sprd9eLdYxVSgQQcGkDtCfm1AoluIpIc-PfM-BEHUKty4LKKxs5u4vlijyee7yPki8htK0VVsVaUmvG2HDDFK8GM2LNWV0Zppw14MBYnv-r9ER_1erH-Ptme1dNgA19j5ewTvL28KRjgNfgcruB1uP6X348Y6id1E5SGdrlW1EUxCzx4NcVzbx0KG9eH55gOgFHFWVDbG6-I4w6Yo87SDGscUdEDE-nXt1krkU8hQ1qJWYbJ9uyIpQesBrj7EmWqUXkiypDPXNZBdo6ZIiUf71FWeG0pnekoP5fQ5lK548vFbVxjMeqO54jBdpPgPQ6VJuPLK7jdsvdPb_0tu-ur1SRHzl21n1-IrZ-YOf7VXITEZ5i5PcFTQKjnzwrzMMzjvub80QoxKJFgVXMzh0CoqO8tIzAc0z8OFxAYAoC9iMy_Wx-wdcemPulD7IXh-fB4mQAoBlURKXLL5lv6EEhJHd74YHvjwpzT12Q97E_odw-sN6Rnuw3ychj98pZMHgOMBoDRCLCvh-e7NIGLOnDRJbionNMELurBRR24KIKLroLrHTn7MTodHrCg2sE07L7nTCoDQTBvYPWCrUIB26Jc1rwp92opTKFyq0QuSzAq5HpspYLvXUs85SEa22hRvCcvuklnPxKqStUaWZpK25Zb6Au9C5FXtpLQUzeb5IMfq4upp2a5iKO49deWT-RVAtg2WWvhd293SH9mFp-dt-4AVOaBgg |
link.rule.ids | 782 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=L-selenomethionine+reduces+platinum%28IV%29+anticancer+model+compounds+at+strikingly+faster+rates+than+L-methionine&rft.jtitle=Dalton+transactions+%3A+an+international+journal+of+inorganic+chemistry&rft.au=Huo%2C+Shuying&rft.au=Dong%2C+Jingran&rft.au=Shen%2C+Shigang&rft.au=Ren%2C+Yanli&rft.date=2014-11-07&rft.eissn=1477-9234&rft.volume=43&rft.issue=41&rft.spage=15328&rft_id=info:doi/10.1039%2Fc4dt01528b&rft_id=info%3Apmid%2F25075569&rft_id=info%3Apmid%2F25075569&rft.externalDocID=25075569 |